NAD+

Limited Safety Data Available

The safety profile for NAD+ supplementation remains poorly characterized due to limited clinical evidence. The available research consists primarily of mechanistic studies and a small number of completed clinical trials, making it difficult to establish comprehensive safety parameters.

Known Side Effects

Evidence for specific side effects is thin. The completed clinical trials identified (NCT03423342 in heart failure, NCT04907110 in exercise contexts) have not provided publicly available detailed safety reporting. Without access to these trial results, documented side effects cannot be reliably established from the current evidence base.

Contraindications

No specific contraindications have been definitively established based on the available evidence. This represents a significant knowledge gap rather than confirmed safety.

Drug Interactions

The evidence provided does not contain sufficient information to identify specific drug interactions. Given NAD+'s role in cellular metabolism and its interaction with various enzymatic pathways (including sirtuins and PARP enzymes as mentioned in the research), potential interactions likely exist but are not well-documented in the available literature.

Populations That Should Exercise Caution

Due to insufficient safety data, the following populations should be particularly cautious:

• Pregnant and nursing women - No safety data available
• Children and adolescents - No pediatric safety studies identified
• Patients with metabolic disorders - Given NAD+'s central role in metabolism, effects in these populations are unpredictable
• Patients taking multiple medications - Unknown interaction potential

Evidence Limitations

Important disclaimer: The safety evidence for NAD+ supplementation is extremely limited. The research provided focuses primarily on mechanistic pathways rather than clinical safety outcomes. Most studies are preclinical or theoretical, and the few clinical trials identified lack accessible safety reporting.

Anyone considering NAD+ supplementation should consult with a healthcare provider, as the current evidence base is insufficient to establish a comprehensive safety profile. More rigorous clinical trials with detailed safety monitoring are needed to properly characterize the risk-benefit profile of NAD+ supplementation.